Glenmark advances multi-country phase 3 clinical trial of Trastuzumab rezetecan in PROC EP News Bureau Jul 2, 2026 Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its…
